New Study Shows Potential Benefits of Screening All New Cancer Patients for Hepatitis

This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.

January 17, 2019, USA: “Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices”
By Scott D. Ramsey, MD, PhD; Joseph M. Unger, PhD; Laurence H. Baker,DO; et al

This study of 3051 patients attempted to determine the prevalence of chronic hepatitis B virus, hepatitis C virus, and HIV infection among patients with newly-diagnosed cancer. It found 0.6% prevalence of chronic hepatitis B, 2.4% prevalence of hepatitis C, and 1.1% prevalence of HIV. 42.1% of those found with chronic hepatitis B were newly-diagnosed through this screening, 31% of those found with hepatitis C were newly-diagnosed, but only 5.9% of those with HIV were newly-diagnosed. Consequently, the study determined that screening those newly-diagnosed with cancer for hepatitis B and hepatitis C “may be warranted”, though screening them for HIV probably is not. Read article: https://jamanetwork.com/journals/jamaoncology/article-abstract/2721238